Longeveron said it held a constructive Type C meeting with the U.S. FDA regarding its Phase 2b ELPIS II trial of laromestrocel (Lomecel-B) in hypoplastic left heart syndrome. The update suggests ongoing regulatory engagement for the program, but it does not include trial data, approval, or a change in guidance. The news is supportive for sentiment but likely limited in immediate market impact.
Longeveron said it held a constructive Type C meeting with the U.S. FDA regarding its Phase 2b ELPIS II trial of laromestrocel (Lomecel-B) in hypoplastic left heart syndrome. The update suggests ongoing regulatory engagement for the program, but it does not include trial data, approval, or a change in guidance. The news is supportive for sentiment but likely limited in immediate market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
